Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment in lung adenocarcinoma. However, whether patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin J Cancer
Main Authors: Yu, Jiang-Yong, Yu, Si-Fan, Wang, Shu-Hang, Bai, Hua, Zhao, Jun, An, Tong-Tong, Duan, Jian-Chun, Wang, Jie
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802875/
https://ncbi.nlm.nih.gov/pubmed/27001083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0086-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados